Oncology
Phase 3 trials, immunotherapy, antibody-drug conjugates, targeted therapies, solid and hematologic tumors, screening and regulatory approvals.
Published issues
- What's next in oncology — November 14, 2026
This issue brings together four oncology milestones with verifiable dates between November 30, 2026 and April 9, 2027: three FDA decisions (PDUFA target dates announced by the companies) and full data from two phase 3…
🎧 ListenAudio newscast · 3:19 min - Monthly oncology bulletin — November 4, 2026
Colleagues: this issue covers October 5 to November 4, 2026; one item dated before that window is flagged as outside the period. The month was dominated by the ESMO 2026 Congress (Madrid, October 23–27) and by several…
🎧 ListenAudio newscast · 6:50 min - What's next in oncology — October 14, 2026
This edition covers five milestones with verifiable dates between mid-November and late December 2026: four pending FDA decisions (lung, breast and myeloma) and the San Antonio Breast Cancer Symposium. PDUFA dates are…
🎧 ListenAudio newscast · 4:36 min - Monthly oncology bulletin — October 4, 2026
Period covered: September 4 to October 4, 2026. The month was dominated by the IASLC World Conference on Lung Cancer (WCLC, Seoul), the International Myeloma Society annual meeting (IMS, Glasgow, September 23–26), and…
🎧 ListenAudio newscast · 6:05 min - Monthly oncology bulletin — September 28, 2026
Period covered: August 29 to September 28, 2026. The month was dominated by the World Conference on Lung Cancer (WCLC 2026, Seoul, September 12–15), the International Myeloma Society meeting (IMS 2026, Glasgow,…
🎧 ListenAudio newscast · 6:17 min